Patrick Prendergast - Canopus BioPharma Chairman CEO
| CBIA Stock | USD 0.0001 0.00 0.00% |
Insider
Patrick Prendergast is Chairman CEO of Canopus BioPharma Incorporated
| Phone | 353-627-8674 |
| Web | http://www.canopusbiopharma.com |
Similar Executives
| Showing other executives | INSIDER Age | ||
| Karen King | Aramark Holdings | 64 | |
| Calvin Darden | Aramark Holdings | 69 | |
| Lauren Harrington | Aramark Holdings | 50 | |
| Debbie Albert | Aramark Holdings | N/A | |
| Deborah Albert | Aramark Holdings | N/A | |
| Bridgette Heller | Aramark Holdings | 59 | |
| Rahul Sharma | Odyssey Marine Exploration | N/A | |
| Carl Mittleman | Aramark Holdings | N/A | |
| Christopher Jones | Odyssey Marine Exploration | 50 | |
| Paul Hilal | Aramark Holdings | 54 | |
| Christopher Schilling | Aramark Holdings | 52 | |
| Jack Donovan | Aramark Holdings | 67 | |
| Susan Cameron | Aramark Holdings | 62 | |
| Greg Creed | Aramark Holdings | 63 | |
| Arthur Winkleblack | Aramark Holdings | 63 | |
| Chris Schilling | Aramark Holdings | 47 | |
Canopus BioPharma Leadership Team
Elected by the shareholders, the Canopus BioPharma's board of directors comprises two types of representatives: Canopus BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Canopus. The board's role is to monitor Canopus BioPharma's management team and ensure that shareholders' interests are well served. Canopus BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Canopus BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leo Prendergast, COO Director | ||
| Patrick Prendergast, Chairman CEO | ||
| BPharm MSc, Chief Officer | ||
| Elizabeth B, Pres Division |
Canopus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Canopus BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Shares Outstanding | 9.3 M | |||
| Net Income | 1.68 M | |||
| Cash Flow From Operations | 1.98 M | |||
| Beta | -2.23 | |||
| Market Capitalization | 364.56 K | |||
| Total Asset | 1.56 M | |||
| Retained Earnings | (10.29 M) | |||
| Current Asset | 92 K | |||
| Current Liabilities | 2.36 M | |||
| Z Score | -8.4 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Other Information on Investing in Canopus Pink Sheet
Canopus BioPharma financial ratios help investors to determine whether Canopus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canopus with respect to the benefits of owning Canopus BioPharma security.